To further determine whether KRAS mutation confers NSCLC drug resistance through the KRAS/ERK/JNK/ALKBH5 PTMs/m6A/DDB2 and XPC/NER signaling axis in vivo, we carried out xenograft experiments with NSCLC cells. Here, KRAS is linked to non-small cell lung carcinoma.